PAC-1 for Uveal Melanoma

"According to the info on clinicaltrials.gov, this particular trial has ceased its recruiting efforts. The posting was put up in January of 2021 and last updated in November of 2022. Despite these findings, there are still 774 other studies actively seeking participants right now."

"This medical investigation is no longer recruiting. It was initially posted on the 11th of January 2021 and last updated on November 15th 2022. If you are still looking for trials, there are currently 756 studies accepting patients with uveal neoplasms and 18 clinical investigations actively enrolling participants in relation to PAC-1."

"Currently, 18 clinical trials are being conducted to examine the efficacy of PAC-1. Of those studies, 3 are currently in Phase 3 and there is a total of 1592 sites where these experiments take place; Portland, Oregon houses the majority of them."

"Genentech, Inc., the sponsor of this trial, has indicated that Phase 1b: Determine Maximum Tolerated Dose (MTD) will be measured as its primary outcome over a 3-month period. Secondary outcomes to be evaluated include Duration of Response (DoR), Overall Survival (OS), and Overall Response Rate (ORR). DoR is established by documenting complete or partial response until disease progression occurs; OS is calculated from treatment commencement with PAC-1 in conjunction with entrectinib to death due to any cause; ORR is the sum of subjects displaying either full or partial responses under RECIST 1."

"At present, 18 PAC-1 trials have been initiated in 482 cities and 54 countries. The initial examination of this drug was conducted under the auspices of Hoffmann-La Roche in 2015 with a sample size of 700 people. It completed Phase 2 clinical approval and since then there has been 8 additional studies done on it."

"The therapeutic measure is commonly managed with PAC-1, which can also work to abate the symptoms of ailments such as tumors and malignant neoplasms."